Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells

BIOLOGICAL2 trials

Sponsors

University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Lupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, SystemicType 1 Diabetes Mellitus

Phase 1

T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

CompletedNCT01210664

University of California, San FranciscoType 1 Diabetes Mellitus

Start: 2010-11-30End: 2017-01-31Updated: 2018-07-11

Autologous Polyclonal Tregs for Lupus

TerminatedNCT02428309

National Institute of Allergy and Infectious Diseases (NIAID)Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic

Start: 2015-08-27End: 2018-10-03Updated: 2019-11-12

Related Papers

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

JCI Insight2021-07-29197 citations